Cancer is a group of diseases that affects 1.6 million and kills nearly 600,000 Americans each year. The National Cancer Institute defines it as "diseases in which abnormal cells divide without control and can invade nearby tissues" and it is often treated with one or more of the following: chemotherapy, radiation, surgery. The expense for these treatments is expected to rise to $156 billion by 2020. Localized delivery can improve effectiveness and cancer survival rates, decrease the cost of treatment, and decrease the side effects of chemotherapy. This paper addresses models for this localized delivery through nanoemulsions. Nanoemulsions are a spherical layer of a hydrophobic substance holding and surrounded by hydrophilic substances or a spherical layer of a hydrophilic substance surrounded by and holding hydrophobic substances with a diameter less than one micrometer. Nanoemulsions are in development for cancer treatment due to their thermodynamic stability, which improves shelf-life.
functions and kill cancer cells selectively. When taken into healthy cells, AS1411 is removed through exocytosis or efflux instead of damaging them. Using AS1411 on nanoemulsions should cause the cancerous cells to actively absorb the nanodroplets while limiting uptake by healthy cells.
Ultrasound-induced vaporization is also explored as a way to cause nanoemulsions to release their payload into cancer cells. Vaporization of the nanoemulsion droplets weakens surrounding membranes and forces drugs out of nanoemulsions as microjets. This method can be used on many cancers, especially those near to the skin as there is less interference. One caveat is that ultrasound may not be safe for lung cancer treatments, as ultrasound cannot penetrate air in the lungs and the reflected waves may damage healthy lung tissue. These additions to systemic nanoemulsion treatment, both combined and separate, are tested on both traditional single-layer v MDA-MB-231 breast cancer cells and on artificially grown tumors, called spheroids. This spheroid testing allows for a look into how these treatments may be affected by avascular tumors, which are more drug resistant than normal cancer.
To test the effects of these treatment options, FITC-labeled or doxorubicin-loaded nanoemulsions were produced and applied on top of the cancerous cells. Doxorubicin was used due to its chemotherapeutic properties and its lack of interference with MTT assay readings. Some samples were created with AS1411 covalently bound to the outside while others were created with no payload or targeting to act as a control. After a period of incubation the nanoemulsions in some samples are ultrasonicated while others remain untouched as control. Following further incubation, the cells were harvested and assayed for analysis, using flow cytometry for FITC detection and an MTT assay for doxorubicin-induced cytotoxicity detection.
The results of these tests showed that ultrasound improved cytotoxicity in doxorubicintreated spheroids but worsened FITC uptake. This reduced FITC uptake may be caused by holes in the cell membrane induced by ultrasound, allowing FITC to leak back out of the cells. AS1411, both with and without ultrasound, had an insignificant effect on cytotoxicity in this study. The lack of consistent improvement by AS1411 may be due to the use of cancerous cells exclusively in our spheroids, which result in all of the nanoemulsions releasing their payloads onto the cancer regardless of whether or not they bind to their nucleolin. Another theory is that the incubation times were too long, so the passive uptake of the nanoemulsions was able to overshadow to the active uptake stimulated by AS1411. The results of this research encourage further study into the potential efficacy of these treatment options. It is a growing global concern and is now responsible for one in every six deaths, making it the second leading cause of death worldwide (WHO). The market for cancer treatment in the United States is growing (NCI) and new treatments are constantly in development. Traditional chemotherapy kills rapidly multiplying cells, which also results in damage to normal tissues, such as bone marrow, hair, and digestive tract tissues (ACS). To enhance the effectiveness of chemotherapy on cancerous cells and limit these side effects, targeted delivery is being researched. This paper addresses adaptations to nanoemulsion delivery to become a targeted therapy.
Nanoemulsions are a type of nanoparticle where a layer of hydrophobic material surrounds a hydrophilic core or a hydrophilic material surrounds a hydrophobic core. These particles can be used as drug vehicles to protect and carry chemotherapies throughout a body. Nanoemulsions are also small enough (50-200 nm) to pass through leaky vasculature and accumulate in tumors, resulting in higher delivery to cancer cells (Zhou) . Ultrasound can be applied to perfluorocarbonbased nanoemulsions and can cause them to vaporize due to the low boiling point of the perfluorocarbon. This process can induce cavitation of the vaporized droplets, which can result in microstreaming and enhance drug delivery to nearby cells whose membranes were permeabilized by the ultrasound (Zhou) . While vaporization and cavitation cannot target individual cell types, ultrasound can be focused to an area to specifically vaporize nanoemulsions there, resulting in localized delivery.
AS1411 is an aptamer discovered by Bates et al. which binds to nucleolin. It is 26 nucleotides long and reads 5'-GGTGGTGGTGGTTGTGGTGGTGGTGG. AS1411 is removed via efflux in normal cells, but in cancer cells is absorbed by micropinocytosis and increases in concentration (Bates) . AS1411 also binds to nucleolin that appears on the membranes of cancer cells, allowing it to function as a targeting molecule (Luo et al.) .
Spheroids are artificially grown tumors. The use of spheroids in these experiments should allow for greater understanding of how these treatments will function in a 3D environment before performing in vivo experimentation (Ivascu) . Ultrasound cavitation, due to the creation of microjets, should be able to deliver drugs further into spheroids compared to spheroids not treated with ultrasound. Concerns have been raised that this cavitation could break cells off the tumor and induce metastasis, but no tests have been performed yet to verify this concern. If this is also true in vivo, ultrasound should improve the speed at which drugs kill cancer cells and give the cancers less time to metastasize. While AS1411 is not anticipated to have an additional effect on spheroids compared to flat tissue, spheroids should provide a more accurate model of drug delivery for in vivo comparisons. A photo of one spheroid from this lab is presented below as Figure 1 . into tumors has been tested before using fluorescent compounds, PGG-PTX, which is a nanoparticle-forming chemotherapy drug, and spheroids (Luo, et al.) . The use of nanoemulsions to improve drug delivery to spheroids has also been tested, such as in the treatment of human mammary cancer cells with photodynamic therapy (Muehlmann, et al.) . This project offers greater insight into how to improve cancer therapies by combining these augmentations to traditional therapy and testing the combined treatment against both controls and the two augmentations alone. This is improved by the use of spheroids to simulate the three-dimensional tissue growth of tumors in vivo.
INSTRUMENTATION AND EQUIPMENT
Spheroid Production:
Spheroids were produced using MDA-MB-231 human breast carcinoma cells. Additional materials used were Trypsin-EDTA 0.05% (1 mL Trypsin-EDTA 0.25%: 4 mL PBS), sterile PBS, deionized (DI) water, Dulbecco's Modified Eagle Medium (DMEM) cell culture media, dry agar powder, autoclave-safe 250 mL flasks, an autoclave, a microwave, a sterile hood, 24-well and 96-well plates, 96-well Corning ultra-low attachment spheroid plates, a hemocytometer, a shaker with speed of at least 120 rpm, a centrifuge with speed of at least 1500 rpm, pipettes, and pipette tips.
MTT Assay Protocol:
To perform the MTT assay, the following materials were used: MTT solution, lysis buffer, Trypsin-EDTA 0.25%, a plate reader, pipettes, and pipette tips.
Cell Splitting/Harvesting
To split and harvest cells the following materials were used: 10/25 mL cell flasks, MDA-MB-231 Cells, Trypsin-EDTA 0.25%, Sterile PBS, deionized (DI) Water, Dulbecco's Modified Eagle Medium (DMEM) media, a sterile hood, formaldehyde, pipettes, and pipette tips.
Nanoemulsion Production
To produce nanoemulsions, the following materials were used: Cy5-AS1411 aptamer, AS1411- by adding DI water while the solution was being heated. The final solution was stirred with a magnetic stir bar until thoroughly mixed. The agar solution, still loosely capped, was autoclaved for 15 minutes at 121 o C using slow exhaust. The bottle was removed from the autoclave and allowed to cool prior to the cap being tightened. The solution was stored at room temperature.
Agar coating of non-tissue culture treated plates (sterile conditions):
The agar was warmed to its melting point (approximately 70 o C) by microwaving it at 30 power for 3 minutes followed by 100% power for 30 seconds. 200 µL (for a 24-well plate) or 100 µL (for a 96-well plate) of the agarose was pipetted into each well of a plate. The agar was pipetted up and down a few times in the hot agar to avoid dripping. The pipetting was done with smooth movement around the well. The tip of the pipet was changed every 12 samples to avoid agar building up and blocking it. The plate was stored at room temperature under sterile condition. After a few hours, the plate was checked to see if the agar had fully solidified, so cells could be plated.
Create spheroids (sterile conditions):
Human cancer (MDA-MB-231) cells were detached from 80% confluency using 0.05% trypsin.
The cells were counted and centrifuged at 1500 rpm for 5 minutes in 4 o C. The amount of DMEM required for a final cell concentration of 100,000 cells/mL (24-well plate) or 60,000 cells/100 µL (96-well plate) was calculated using the cell count. The trypsin was aspirated and the cells were suspended in the amount of DMEM calculated. In the event that far more DMEM was required to dilute the cell count than was needed to grow spheroids, some of the cells would be discarded. 1 mL (24-well plate) or 100 µL (96-well plate) of cells and media were pipetted into each well of a round bottom ultra-low attachment plate (Corning Inc., Corning, NY, USA) or an agar treated flat bottom plate created in a previous step. The lid was placed on each plate and the plate was shaken at 120 rpm for 15 minutes to allow for aggregation. The cells were incubated for 37 o C for 3 to 7 days.
Spheroid treatment and disaggregation:
After the spheroids were formed, various concentrations of treatments were applied to each well after being diluted to 1 mL per well (24-well plate) or 100 µL per well (96- 
Cell Splitting
The source flask was examined under a microscope and the confluency of the cells was estimated.
Cells were harvested when between 80%-90% confluency. 0.25% Trypsin and DMEM media were warmed to room temperature in a water bath. The source flask was held upside down and tiled so that the cap faced upwards. The cap was unscrewed and the media was aspirated from the corner it was in (not a corner cells had grown on). Touching the sides of the flask the cells grew on was avoided. The flask was washed with 3 mL PBS (10 mL flask) or 10 mL PBS (25 mL flask) before the PBS was aspirated using the stated technique. 3 mL (10mL flask) or 10 mL (25 mL flask) of 0.25% Trypsin-EDTA was added to the flask. If the cells were to be used in spheroid production immediately, 0.05% Trypsin-EDTA was used instead, as per the spheroid protocols our lab uses.
The cells were incubated at 37 o C for 1 minutes (0.25% trypsin) or 3 minutes (0.05% trypsin). The side of the flask was tapped vigorously to shake the cells loose and the flask was placed under a microscope. If some of the cells were not moving, the flask was tapped more. If, after two rounds of tapping, some cells still remained immobile, the flask was incubated for an additional minute before being tapped again. The trypsin was neutralized with 3 mL of DMEM for 10 mL flasks (the 25 mL flasks did not require neutralization before transfer). A cell count was performed if required.
X mL of cells were moved to the new flask and 10-X mL media was added to the new flask where 
Ultrasound Testing
Fluorescent nanoemulsions were produced and applied to both single-layer and spheroid cancer cells. After 1 hour, half of the nanoemulsions were placed under ultrasound treatment for a fixed period of time. A one hour waiting period was chosen to allow for the nanoemulsions to potentially bind to receptors on the spheroid without too much passive uptake into the cells. Both ultrasound-treated and non-ultrasound treated emulsions were then be placed in incubation for an additional 2 days before results were obtained. Some samples were examined via flow cytometry.
Other samples were sent through a plate reader for fluorescent reading.
RESULTS AND DISCUSSION OF RESULTS
Spheroid Production:
Spheroids were produced with two methods to determine which was more consistent. The first method involved treating a normal 96-well plate with agar before attempting to grow cells. The second method was to use specially made spheroid plates with round, treated bottoms to prevent cell attachment. Spheroid size and shape were visually examined and photos were taken of both results. The method that produced uniformly sized spheroids with low aspect ratios was used in additional experiments. It was found that the spheroid plates performed better, as their round bottoms and surface treatments encouraged more consistent aggregation. As evidenced by Figure   2 below, there is not a statistical difference between using 10k of cells and 15k of cells.
Additionally, there is no statistical difference between using 5 and 50 µM of doxorubicin, though there is a difference between Control and every other concentration and 0.5 µM and every other concentration when testing the various sized spheroids.
Figures 3 and 4 show the shape of spheroids and how high concentrations of doxorubicin disaggregate them. Figure 5 shows why other experiments were performed after 28 hours of treatment, as the standard deviation for MTT absorbance was consistently smaller with less time.
The nanoemulsion data was not normal, so ANOVA could not be performed, but they do show that for liquid doxorubicin the control group and 5 µM liquid doxotubicin group there is no statistical difference in absorbance, but there is a difference between each of 50 µM and 25 µM and the others. show no difference between one day and one week as each is within one standard deviation of the other. After two weeks, significant leaking of the FITC was seen and fewer cells were marked when total cell association was tested after washing.
Doxorubicin was used for the drug tests due to its chemotherapeutic properties.
Doxorubicin has an IC50 Z-Score of 1.16291 on MDA-MB-231. A Z-Score of 2 or above indicates the cell line is resistant to the drug while a Z-Score of -2 or below indicates it is sensitive to the drug (Cancer RxGenes). The effect of doxorubicin on these cells has also been shown experimentally in our lab during a previous experiment. In Figure 6 , the percent viability of flat MDA-MB-231 cells can be seen decreasing as doxorubicin concentration increases. far from a normal distribution to perform an ANOVA. Figure 10 shows an unexpected increase in absorbance as doxorubicin concentration increases, but this may be due to doxorubicin being a similar color to the product of MTT assays, resulting in false positives.
Since the goal of this experiment was to determine the effects of ultrasound and the samples are compared against those treated with the same amount of doxorubicin, this does not change the conclusion. would be ultrasound, followed by AS1411, as AS1411 is expected to less of a noticeable effect without noncancer cells to differentiate cancer from. Finally, the control is expected to have the least fluorescence. We can see in Figure 11 below that the ultrasound-treated cells had consistently lower fluorescence intensity than the non-ultrasound treated cells and that AS1411 improved the cell counts. Figure 11 was normalized to the untargeted, nonultrasonicated samples as untreated samples were not used in this experiment. A similar experiment that shows how these treatments compare to a control can be seen in Figure 7 .
This can be explained as the ultrasonication creating holes in the cells allowing for the FITC to escape. Testing this on spheroids, as seen in Figure 12 , shows less effect. The
FITC intensity could not be tested in ANOVA due to a low R-squared value, while the Cy5 Figure 11 and spheroids in Figure 12 or the immediate fixing of the cells in Figure 12 's experiments. Unfortunately, no cause for these abnormalities have been found. Additional testing may find these to be outliers. Additionally, ANOVA could not be performed, as the residual tests were failed as seen in Figure 14 . Specifically, the normal probability plot deviated from the center line drastically and the versus fit is drastically large on the right side. 
CONCLUSIONS
Cancer continues to be a major source of mortality worldwide. This paper has presented a plan to test two methods of localizing drug delivery in nanoemulsions. Combined, these methods may result in fewer side effects for current and future cancer patients. AS1411 surface modification has the potential to result in greater uptake into cancer cells specifically and greater accumulation around the tumor. Ultrasound-induced vaporization of nanoemulsions has the potential to increase penetration into the spheroid and increase drug uptake. Neither of these methods should affect healthy tissue, although the ultrasound is area specific and could injure healthy tissue adjacent to the tumor. The use of spheroids should result in more accurate comparisons to in vivo conditions.
RECOMMENDATIONS
The results of this study leave many areas for future research. While the combined effects of AS1411 and ultrasonication showed little increase compared to ultrasonication alone, this study was limited by the use of only cancerous cells. Future studies can experiment using cancerous spheroids and healthy tissue to see if AS1411 will encourage drug delivery to cancerous cells over healthy cells. Similarly, this experiment could be performed with an artificial circulatory system to see if the AS1411 will hold the nanoemulsions to the spheroids long enough for a high concentration to build up there so that only a short period of ultrasonication is necessary for treatment. If AS1411 is shown to contribute to the selectivity of the drug's effects, in vivo testing in animals may be warranted. This study has yielded initial results on ultrasound's ability to improve drug delivery in tumors in vivo and has revealed potential complications to avoid when testing the effects of AS1411 on nanoemulsions. Additional studies may include testing other chemicals to target cancer besides AS1411 and see how they influence uptake with ultrasound.
There is some concern that the physical structures of spheroids prevent MTT from reaching cells in the center, skewing cell viability results. This was not anticipated in this paper and was not accounted for, which may have resulted in the effects of the drugs being stronger than recorded here. Future tests should involve a step disaggregating the spheroid without harming the cells prior to MTT application. Other studies have used the CellTiter-Glo Luminescent Assay to disaggregate the spheroids through lysis and determine the relative number of viable cells prior to lysing using the ATP that was in the cells. There was also concerns that doxorubicin could interfere with the absorbance of the crystals from the MTT assay. An absorbance test was performed, and while doxorubicin does show some absorbance at 570nm, it is very minor, with its peak absorbance being between 480 and 490 nm. Concerns were also raised that doxorubicin may be too easy of a drug to enter cells, thus negating some of the effects of the drug delivery mechanisms. Due to these concerns, it is suggested that future studies consider using other drugs to determine if these concerns are valid.
Additional concerns are that the ultrasonication of nanoemulsions could induce metastasis by breaking cells off the tumor and that the large nanoemulsions may impede uptake into spheroids. Future tests could verify the first concern by using MTT to test the viability of cells that break off from the spheroid during ultrasound treatment. Further testing with smaller nanoemulsions can test the effect of the second concern.
